IONIS PHARMACEUTICALS INC 8K

Ionis disclosed that partner Novartis’ Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular outcomes endpoint despite achieving substantial Lp(a) reduction, though safety was acceptable.

On September 4, 2026, Ionis Pharmaceuticals, Inc. reported that its partner Novartis announced topline results from the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial of pelacarsen, indicating that although the drug substantially lowered lipoprotein(a) levels in patients with elevated Lp(a) and established cardiovascular disease who were receiving guideline-directed care, the study failed to meet its primary composite endpoint of reducing major adverse cardiovascular events versus placebo; pelacarsen showed an acceptable safety profile, full data will be presented at a future medical congress, and Ionis emphasized its ongoing focus on independently commercializing its wholly owned medicines and advancing its broader pipeline.

Filing Facts

CIK

874015

Ticker

IONS

Form

8K

Source Type

fda

Accession

0001140361-26-035802

Alert Tier

7